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Summary. The purpose of the present study was to analyze 
the effects of cromakalim (BRL 34915), a potent drug from 
a new class of drugs characterized as"K + channel openers", 
on the electrical activity of human skeletal muscle. There- 
fore, intracellular recordings were used to measure the ef- 
fects of cromakalim on the membrane potential and input 
conductance of fibres from human skeletal muscle biopsies. 
Cromakalim in a concentration above 1 gmol/1 induced an 
increase in membrane K + conductance. This effect resulted 
in a membrane hyperpolarization. The magnitude of this 
polarization depended on the difference between resting and 
K + equilibrium potential. The effect had a rapid onset and 
was quickly reversible after washing. Fibres from two 
patients with hyperkalaemic periodic paralysis howed an 
excessive membrane depolarization during and also after 
exposure to an slightly elevated extracellular K + concentra- 
tion. In the latter situation, cromakalim repolarized the fibres 
to the normal resting potential. Tolbutamide (1 retool/l) 
and Ba 2+ (3 retool/l) strongly antagonized the effect of 
cromakalim. The data show that cromakalim hyperpolarizes 
depolarized human skeletal muscle fibres maintained in 
vitro. The underlying mechanism is probably an activation 
of otherwise "silent", ATP-regulated K + channels. Such an 
effect may be of therapeutic benefit in a situation in which 
a membrane depolarization causes muscle paralysis. 
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Introduction 
A new class of drugs characterized as"K + channel openers" 
(Weston and Abbott 1987) has been described to influence 
the electrical and mechanical ctivity of a variety of smooth 
muscles (Hamilton et al. 1986; Weir and Weston 1986; Kreye 
et al. 1987; Quast 1987; Hollingsworth et al. 1987) and 
cardiac muscle (Escande t al. 1988; Osterrieder 1988). One 
potent drug from this group is cromakalim (BRL 34915). 
This compound also shows effects upon convulsive dis- 
charges in guinea pig hippocampal slices (Alzheimer and ten 
Bruggencate 1988). The present study was concerned with 
two experimental questions: (a) Does cromakalim influence 
electrophysiological p rameters of human skeletal muscle? 
In particular, effects on diseased human muscle would be of 
interest and may lead to new therapeutic strategies. (b) How 
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does cromakalim activate the K + conductance of skeletal 
muscle? To answer these questions we performed elec- 
trophysiological recordings from human skeletal muscle bi- 
opsies maintained invitro (Iaizzo and Lehmann-Horn 1988). 
The results of the present study show that cromakalim 
hyperpolarizes human skeletal muscle via an increase in 
membrane K + conductance. The effect on membrane poten- 
tial can be seen more clearly when the potential deviates 
from the potassium equilibrium potential. Furthermore, the 
effect of cromakalim was blocked by tolbutamide. This may 
indicate that cromakalim activates otherwise "silent", ATP- 
regulated K + channels (Sturgess et al. 1985; Stanfield 1987; 
Ashcroft 1988; Escande t al. 1988). 
Methods and Materials 
The experiments were performed on biopsies of human skel- 
etal muscle (Iaizzo and Lehmann-Horn 1988). Fibre seg- 
ments (4 -6  cm long) were removed from biceps brachii, 
deltoid, vastus medialis or vastus lateralis muscles under 
local anaesthesia. Such segments were obtained from: (1) 
patients who consented that a muscle biopsy be carried 
out for the in vitro diagnosis of susceptibility to malignant 
hyperthermia; (2) patients who require a muscle biopsy for 
clinical diagnosis; and (3) patients with a known neuro- 
muscular disease who consented to have a muscle biopsy 
removed for experimental reasons only. All procedures were 
in accordance with the Ethics Committee of the Technische 
Universit/it Miinchen. 
The preparations were transferred to a perspex chamber 
(volume 2 ml, flow rate 6.5 ml/min) and superfused at 36°C 
with a solution (Bretag 1969) of the following composi- 
tion (in mmol/1): NaCl107.7; CAC121.53; KC13.48; 
MgSO4 0.69; NaHCO3 26.2; NaH2PO4 1.67; Na-gluc- 
uronate 9.64; glucose 5.5; sucrose 7.6 (bubbled with 95% 
02/5% CO2; pH 7.4). Most of the muscle fibres were im- 
paled midway with two microelectrodes for recording of 
membrane potential and injection of current, respectively. 
Intracellular micro-electrodes were drawn on a DMZ uni- 
versal puller (Zeitz Instrumente, Augsburg, FRG) and filled 
with 3 tool/1 KC1 (5 -10  M~). An Axoclamp 2 (Axon In- 
struments, Burlingame, CA, USA) was used to inject current 
and to record membrane potential. Data were recorded and/ 
or stored on a digital oscilloscope (Nicolet 4094, Offenbach, 
FRG), a chart recorder (W + W recorder 316; Kontron, 
Miinchen, FRG), and a tape recorder (TEAC XR-310; nbn 
Elektronik, Herrsching, FRG). 
Drugs were applied via the bathing solution. Tolbu- 
tamide was obtained from Sigma (Miinehen, FRG); 
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Fig. 1 A -C .  Cromakalim enhances membrane 
K + conductance. Part A shows a continuous 
recording of membrane potential (Era) and in- 
put resistance of a fibre from a skeletal 
muscle biopsy (no neuromuscular disease). In- 
put resistance was determined every 15 s by 
hyperpolarizing current pulses (40 nA, 1 s). 
B illustrates current-voltage relationships 
taken before, during and after the application 
of cromakalim. The I- V curves before and 
during cromakalim are plotted in part C. Note 
the reversal potential at -95 mV 
cromakalim (BRL 34915) was a gift from Beecham Phar- 
maceuticals (Gronau, FRG). Stock solutions (100 mmol/1 
cromakalim, I mol/1 tolbutamide) were prepared in di- 
methyl sulfoxide (DMSO). DMSO did not mimic the effects 
of cromakalim or tolbutamide, respectively. 
Resu l ts  
Effects of cromakalim were explored on more than 60 fibres 
in skeletal muscle biopsies from 12 persons. The patients 
had the following diseases: myotonic dystrophy, chon- 
drodystrophic myotonia (Schwartz-Jampel syndrome); hy- 
pokalaemic periodic paralysis (2x;  see Fig. 3), hyper- 
kalaemic periodic paralysis (2 x ; see Fig. 5), recessive gen- 
eralized myotonia, amyotrophic lateral sclerosis (see Fig. 2), 
myositis (see Fig. 4), and 3 persons without neurological 
diseases (these muscles were also tested for their sus- 
ceptibility to malignant hyperthermia; see Fig 1). Resting 
membrane potentials in these fibres varied between -55  
and -85  mV. However, in spite of this wide range in resting 
potential, an uniform effect was seen when cromakalim was 
applied via the bathing solution. The effect consisted of a 
membrane hyperpolarization a d an increase in membrane 
conductance. A typical example of the effects of cromakalim 
is illustrated in Fig. I (muscle biopsy was taken from a 
patient without muscle disease). The muscle fibre was im- 
paled with two microelectrodes. One was used for the con- 
tinuous recording of membrane potential; the other one 
served as current-delivering electrode. Hyperpolarizing cur- 
rent pulses (40 nA, 1 s) were applied every 15 s. Further- 
more, current-voltage relationships were determined before, 
during, and after the action of cromakalim. Membrane cur- 
rents itself were not recorded in the present study. The re- 
cording of this parameter would have needed the 3-micro- 
electrode voltage clamp procedure (Adrian & Marschall 
1977) to account for the cable behaviour of the muscle 
biopsies, which had a length of 4 -6  cm. Therefore, all con- 
clusions of the present study are based on changes in mem- 
brane potential and conductance. 
Figure 1 shows that cromakalim produced a membrane 
hyperpolarization and an increase in membrane conduc- 
tance. The current-voltage r lationships revealed a reversal 
potential at -95  mV (see Fig. IC). This indicates an in- 
crease in membrane K + conductance if one assumes no 
important alterations in the conductance of other channels 
during hyperpolarization from -78  to -88  mV. This con- 
clusion is further supported by the observation that 
cromakalim had similar effects when C1--flee bathing solu- 
tions were used (4 observations, not illustrated). An increase 
in membrane K + conductance during cromakalim can also 
be deduced from the finding of an antagonistic effect of 
Ba z+ (see below). 
The effect of cromakalim on the membrane potential 
(Era) was dependent on the difference between resting - and 
K + equilibrium potential (EK). Hyperpolarizations of up to 
30 mV were seen in fibres with resting potentials around 
- 55 mV. On the other hand, in fibres with resting potentials 
of -85  mV, cromakalim had very little effect. Likewise, 
cromakalim did not hyperpolarize the depolarized mem- 
brane of fibres in a solution containing 20 mmol/1 [K+]e. 
Changes in membrane potential in the normal bathing solu- 
tion were used to determine the concentration-response be- 
haviour of cromakalim. For the induction of a big difference 
between Em and EK, blunt electrodes (tip diameter 1.5 gm) 
were used which produced an artificial, unspecific ion leak 
at the site of impalement. Figure 2 shows a typical example 
of such measurements; the observation was made on a 
muscle fibre from a patient with amyotrophic lateral scle- 
rosis. The resting potential of this fibre was -60  mV. 
Cromakalim was applied in concentrations between 10 and 
100 l~mol/1. The drug induced a concentration-dependent 
membrane hyperpolarization. The effect had a rapid onset 
and was quickly reversible. Different concentrations of 
cromakalim were explored on another 22 fibres (application 
time 4 -10  min). In all these recordings a minimal concen- 
tration of 3 gmol/1 was necessary for a cromakalim-induced 
membrane hyperpolarization. 
In a next series of experiments, the effects of the K ÷ 
channel blockers Ba 2÷ and tolbutamide on the action of 
cromakalim were explored. It was found that both, tolbuta- 
mide (1 mmol/1) and Ba 2 + (3 mmol/1, not illustrated) strong- 
ly antagonized the effect ofcromakalim. Figure 3 stems from 
a patient with hypokalaemic periodic paralysis. In normal 
bathing solution cromakalim produced a hyperpolarization 
of 20 mV; this effect was strongly reduced in the presence 
of I mmol/1 tolbutamide. A lower concentration of tolbuta- 
mide (0.3 mmol/1) was less effective. The interaction of tol- 
butamide with the effect of cromakalim was further analyzed 
by means of current-voltage relationships ( ee Fig. 4). These 
recordings revealed, in particular, that tolbutamide itself did 
not have an effect on the steady state membrane conduc- 
tance in the range +_25 mV from the resting potential. 
Figure 4 illustrates five I-V curves recorded consecutively 
from a single fibre (data stem from a patient with myositis). 
First (Fig. 4A), an / -V  curve in the presence of cromakalim 
(100 p.mol/1) was compared with one taken in normal bath- 
ing solution. This revealed an enhancement of membrane 
K + conductance (see also Fig. 1). Figure 4B shows I -V  
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Fig. 2. Effects of cromakalim on membrane potential (Em) of a 
human skeletal muscle biopsy (patient with amyotrophic lateral 
sclerosis). The resting potential of this fibre was - 60 mV. At this 
potential, concentration-dependent hyperpolarizations were in- 
duced by application of cromakalim to the bath 
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Fig. 3. Tolbutamide blocks the effect of cromakalim. The figure 
shows the recording of the membrane potential (Era) of a fibre from 
a human skeletal muscle biopsy (patient with hypokalaemic periodic 
paralysis). Cromakalim (100 gmol/1, r---l) was applied first in the 
normal Bretag solution. It produced a hyperpolarization with a 
rapid onset. This effect was completely blocked inthe presence of 
tolbutamide (1retool/l, I I )  
329 
curves taken 10 rain after wash-out ofcromakalim and 5 rain 
after addition oftolbutamide (1 mmol/1) to the bathing solu- 
tion. Tolbutamide did not show an effect of its own on the 
steady state membrane conductance. However, it strongly 
reduced the effect of cromakalim as shown in Fig. 4C. This 
plot shows I -V  curves in the presence of tolbutamide 
(1 retool/l) and when cromakalim (100 pmol/1) was added 
to a tolbutamide-containing bathing solution. Although 
most of the effect of cromakalim was blocked in this situ- 
ation, there still was a tolbutamide-insensitive eff ct at less 
negative potentials. 
The effect of cromakalim was explored on the de- 
polarized state of fibres from two patients with hyper- 
kalaemic periodic paralysis (h.p.p.). It has been previously 
described that h.p.p, muscle fibres respond with an acti- 
vation of a non-inactivating Na + conductance when [K+]e 
is slightly elevated (Lehmann-Horn et al. 1983, 1987a). As 
a consequence, the membrane depolarizes more than pre- 
dicted by the Nernst equation for a given increase in [K+]c. 
Furthermore, Em remains depolarized even when [K+]c is 
lowered to the normal value. So far, in the in vitro exper- 
iments, only tetrodotoxin (TTX) was able to block this Na + 
conductance and to repolarize the membrane (Lehmann- 
Horn et al. 1983, 1987a). We have now observed that a 
similar effect was induced by cromakalim. Figure 5 illus- 
trates recordings of the membrane potential from h.p.p. 
muscle fibres. First, [K+]e was elevated by 7retool/1 
(Fig. 5 A). This resulted in a strong membrane depolarization 
and no repolarization was seen upon lowering [K+], to the 
normal resting level (3.5 mmol/1). However, the potential 
returned to the resting value soon after the addition of 
cromakalim (100 pmol/1) to the normal bathing solution. 
Later on, the depolarized state was induced a second time; 
this time TTX was used to initiate a membrane repolariza- 
tion. Figure 5 B illustrates a recording of the potential from 
a different fibre. This time, 7 retool/1 K + were added to the 
bathing solution in the presence of 100 gmol/1 cromakalim; 
no abnormal behaviour was found. However, the same fibre 
came into a depolarized state when 7 retool/1 K + were added 
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F ig .  4A  - C. Effects of tolbutamide on the current-voltage (/- V) relationship of a human skeletal muscle fibre (patient with myositis). All 
/- V curves were recorded consecutively from a single fibre (analysis was performed with potential values taken at the end of 1 s current 
pulses). A shows a comparison between I-V curves taken in normal bathing solution and after cromakalim (100 pmol/1) was added to this 
solution (application time 3 rain; a steady state effect was reached). B I -V behaviour recorded 10 min after washing of cromakalim is
compared with an/- V curve in the presence of tolbutamide (1mmol/1, application time 5 min). C/ -  V plots in the presence of tolbutamide 
and 3 min after cromakalim (100 lamol/1) was added to the tolbutamide-containing solution are superimposed 
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Fig. 5A, B. Cromakalim repolarizes the membrane in two different fibres from a patient with hyperkalaemic periodic paralysis (h.p.p.). 
A Addition of 7 mmol/1 K + ( I )  to the normal bathing solution resulted in a depolarization of the membrane; the membrane r mained 
in this depolarized state even after [K +]e was lowered to its normal resting level (3.5 mmol/1; for further explanation see text). Cromakaiim 
(100 gmol/1, if:3) restored the normal resting potential. Such a repolarization was also induced by tetrodotoxin (TTX, 0.6 p,mol/1, [N~]). 
B When 7 retool/1 K + were added in the presence of cromakalim no excessive membrane depolarization was seen. Later on, 7 mmol/l K + 
were added to the normal bathing solution; this induced amembrane depolarization with the typical characteristics of a h.p.p, muscle fibre 
to the normal bathing solution; cromakalim again was able 
to repolarize the membrane. 
Discussion 
The present study shows that cromakalim hyperpolarizes 
human skeletal muscle fibres. Such an effect deserves atten- 
tion since it may be of therapeutic benefit in some kinds of  
skeletal muscle disease. For example, the hyperpolarizing 
effect of adrenaline on skeletal muscle has been shown to 
improve muscle strength in patients suffering from 
hyperkalaemic periodic paralysis (Wang and Clausen 1976; 
Bendheim et al. 1985): Cromakalim also hyperpolarizes 
smooth and cardiac muscle (for references see Introduction). 
In these preparations the action was explained by an increase 
in membrane K ÷ conductance (gK). An enhancement of gK 
can also explain the effect on the membrane of skeletal 
muscle fibres. However, a hyperpolarization of more than 
20 mV, which we have observed in some human muscle 
fibres, apparently seems to contradict such a view, since it 
is well known that the resting potential (Era) in skeletal 
muscle is very close to the potassium equilibrium potential 
(EK; Horowicz and Spalding 1986). Nevertheless, there is 
one experimental situation with a bigger difference between 
Em and EK. The impalement i self creates a leak conductance 
with a reversal potential at 0 mM. The potential at the site 
of the impalement is, therefore, somewhere between the 
normal EK and 0 mV. EK itself does not change very much 
as a result of the electrode leak since the content of K ÷ in 
large cells is very high. If gK increases near the site of 
impalement the leak conductance is short circuited and Em 
shifts close to EK. Indeed, hyperpolarizations in the range 
of 20 mV were only seen in fibres with a resting potential 
of around - 65 mV. However, some of the skeletal muscle 
biopsies had low membrane potentials even when electrodes 
with very fine tip diameters were used. In these situations 
an electrode leak seems unlikely to be the reason for the 
low membrane potential. Cromakalim was able to shift the 
potential of such fibres to around - 85 mV. This indicates 
that also such fibres had a rather normal intracellular K ÷ 
concentration. Therefore, we assume that an abnormally 
high Na +- or low K ÷ conductance, respectively, may have 
caused the low resting potential. The reason for this change 
in the permeability ratio is unclear. 
The next aspect concerns the type of K ÷ channel acti- 
vated by cromakalim. The blocking effect of Ba z+ is in 
accordance with the data of Osterrieder (1988). However, 
Ba 2 + is a rather unspecific K + channel antagonist and this 
observation allows no conclusion which type of K ÷ channel 
may be involved. Tolbutamide, on the other hand, has been 
reported to be a specific antagonist of  ATP-regulated K + 
channels in fi cells of rat islets of Langerhans (Sturgess et 
al. 1985). Tolbutamide did not have an effect of its own in 
our experiments. Nevertheless, it strongly antagonized the 
effect of cromakalim. Therefore, the following conclusion 
seems to be possible: Human skeletal muscle possess 
tolbutamide-sensitive, ATP-regulated K + channels which 
are closed under normal circumstances (Castle and Haylett 
1987; Spruce et al. 1987; see also Belles et al. 1987 for 
data in cardiac muscle). Cromakalim is able to activate 
this conductance. The precise mechanism, however, of this 
interaction remains unclear. The same conclusion was drawn 
in a recent study about the effects of cromakalim on isolated 
cardiac myocytes (Escande et al. 1988). These authors 
showed that the effect of cromakalim was antagonized by 
low concentrations of glibenclamide, another specific 
blocker of  ATP-dependent K ÷-channels. 
Finally, the possible therapeutic use of cromakalim will 
be discussed. An exogenously-induced activation of K ÷ con- 
ductance should have beneficial effects in human skeletal 
muscle diseases. Several muscle diseases have been described 
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in which a membrane depolarization results in muscle pa- 
ralysis (for review see Riidel 1986). In paramyotonia 
(Lehmann-Horn et al. 1987b) and hyperkalaemic periodic 
paralysis (Lehmann-Horn et al. 1987a) the membrane 
depolarization was found to be due to an abnormal increase 
in Na + conductance. In hypokalaemic periodic paralysis, 
on the other hand, a decrease in gK may lead to a membrane 
depolarization (Gallant 1983). In all such situations an in- 
crease in K + conductance should help to repolarize the 
membrane and to improve muscle contraction force. In fact, 
cromakal im was able to repolarize in vitro depolarized fibres 
from a patient suffering from hyperkalaemic periodic paral- 
ysis (see Fig. 5). An enhancement of gK may be also ben- 
eficial in myotonic symptoms. However, the concentrations 
of  cromakal im in our in vitro measurements were rather 
high (gmol/1 range; see Fig. 2). It is possible that the higher 
susceptibility of vascular smooth muscle (nmol/1 range) pre- 
vents a therapeutic effect on skeletal muscle. 
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